Skip to main navigation Skip to search Skip to main content

A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumad in Patients with Prodromal to Mild Alzheimers Disease CREAD-2

Project: Research

Project Details

StatusFinished
Effective start/end date10/9/17 → 10/9/21

Funding

  • Genentech Incorporated: $56,001.00